

## Leukaemia Section

### Review

# Acute myeloid leukemia with myelodysplasia related changes

Alexandra Nagy, Andreas Neubauer

Howard Hughes Medical Institute and the Department Pathology, Beckman Center for Molecular and Genetic Medicine, Stanford University, Stanford, California 94305, USA; anagy2@stanford.edu (A Na); Dept. Internal Medicine and Hematology, Oncology and Immunology, Philipps University Marburg, Germany; neubauer@staff.uni-marburg.de (A Ne)

Published in Atlas Database: January 2017

Online updated version : <http://AtlasGeneticsOncology.org/Anomalies/AMLwithmyelodysplID2041.html>

Printable original version : <http://documents.irevues.inist.fr/bitstream/handle/2042/68997/01-2017-AMLwithmyelodysplID2041.pdf>

DOI: 10.4267/2042/68997

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.  
© 2017 Atlas of Genetics and Cytogenetics in Oncology and Haematology

## Abstract

Acute myeloid leukemia (AML) is a heterogeneous clonal disorder with two prominent features: i) hematopoietic progenitor cells lose the ability to differentiate normally and ii) the transformed leukemia cells show an impaired regulation of myeloid proliferation.

AML with myelodysplasia-related changes is a sub-entity of AML that has a poor prognosis. It is characterized by a history of MDS, significant morphologic dysplasia, or MDS-related cytogenetic features such as  $-7/\text{del}(7q)$  and others. Whereas the prognosis of AML is quite different with respect to genetic aberrations, the therapy - except of acute promyelocytic leukemia (APL) - is still relatively unchanged from 30 years ago. Therefore, new treatment strategies are needed.

### Keywords

Acute myeloid leukemia, multilineage dysplasia, myelodysplasia related changes

## Clinics and pathology

### Disease

Acute myeloid leukemia with myelodysplasia related changes (AML-MRC) is a subgroup of AML. It was introduced in 2008 by the WHO classification and updated in 2016 (Weinberg et al., 2015). A diagnosis of AML-MRC requires  $\geq 20\%$  blasts and additionally one of the following three

criteria:

- history of myelodysplastic syndrome (MDS) or myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
- MDS-related cytogenetic abnormalities or multilineage dysplasia ( $\geq 50\%$  dysplastic cells in  $\geq 2$  hematopoietic lineages) (Arber et al., 2016a).

### Etiology

There are various risk factors which can cause AML in general. These risk factors can be categorized as genetic disorders, physical and chemical exposure, radiation therapy and chemotherapy. Even though many people are exposed, to various degrees, to carcinogens, only a few cases may present with a known history of carcinogen exposure. Currently, it is not fully understood why some people develop AML and some do not (Estey and Döhner, 2006). Genetically, many researchers favor the "two-hit" hypothesis first proposed by Hartmut Beug (Beug et al., 1978), and later by Gary Gilliland. This hypothesis states that for transformation, a mutation in a kinase coding gene such as RAS, KIT or FLT3 has to occur together with a class II mutation targeting a transcription of nuclear factor such as NPM1, RUNX1 or CEBPA. Today, we know about a high variation of somatic mutations and chromosomal abnormalities characterizing different types of AML. AML-MRC is often associated with the following chromosomal abnormalities (Table 1) (Deschler et al., 2006; Weinberg et al., 2015).

## Epidemiology

If the WHO classification is strictly applied, 48% of all adult AML cases meet the AML-MRC criteria. It tends to affect more male and is a disease of the elderly with a median age of 68 years. Additionally, it is associated with a higher frequency of unfavorable cytogenetics and, consequently, a worse clinical outcome (Davis et al., 2013; Xu et al., 2014; Weinberg et al., 2009). AML-MRC occurs more often de novo than secondary to myelodysplasia (Vardiman and Reichard, 2015).

## Cytology

AML-MRC cases commonly present with multilineage dysplasia. This is validated best with peripheral blood smears or bone marrow smears for identifying myeloid and erythroid dysplasia and bone marrow biopsy for identifying megakaryocytic dysplasia (Falini et al., 2016). Following the WHO classification an AML-MRC presents with  $\geq 50\%$  dysplastic cells in at least two hematopoietic lineages. The dysplastic features are not unique for AML-MRC, but can be also detected in other hematopoietic diseases, such as MDS (Wu et al., 2013). Dysplastic neutrophils may exhibit a nucleus-cytoplasm dysynchrony, hypogranulation and abnormal nuclear segmentation (pseudo-Pelger-Huët anomaly), e.g. bi-nucleated segments (Weinberg et al., 2015). As mentioned, dyserythropoiesis and dysmegakaryopoiesis are also commonly seen. Dyserythropoiesis presents with odd erythroid precursors and sometimes ring sideroblasts, as well as multinuclearity, megaloblastoid changes and karyorrhexis. Dysmegakaryopoiesis commonly shows hypolobulated micromegakaryocytes, non-lobulated nuclei in megakaryocytes of all sizes and multiple widely separated nuclei (Wakui et al., 2008).

## Treatment

The therapy of AML-MRC is based on regular AML-therapy with a risk-adapted chemotherapy including induction chemotherapy ("7+3"; daunorubicine plus cytarabine) and postinduction therapy, such as high-dose cytarabine or in high-risk patients, allogeneic transplantation in first remission. Using regular assessments, lab studies including cytogenetics and molecular analyses, the patient can be assigned to a risk group and treatment and prognosis can be determined and the decision between curative chemotherapy/allogeneic stem cell transplantation, palliative chemotherapy and best supportive care can be made (Estey and Döhner, 2006). Chemotherapy can be separated into two main parts. First, the induction therapy with the attempt to reach complete remission. Second, the consolidation therapy to prolong the complete remission. If the patient displays characteristics of high risk AML, a hematopoietic stem cell

transplantation (HSCT) must be considered (Kumar, 2011). As AML-MRC frequently fulfills the high-risk criteria such as: 3(q21q26) abnormalities, RPN1/MECOM (EVI1), del(5q), del(7q), t(6;9), other 11q23 abnormalities, 17p abnormalities, or complex aberrant karyotypes described as at least 3 unrelated abnormalities excluding cases with t(8;21), inv(16), and t(15;17), an allogeneic stem cell transplantation will be the post-induction therapy of first choice in most adults (Vardiman and Reichard, 2015).


## Prognosis

The myelodysplastic changes and MDS associated chromosomal abnormalities of AML-MRC are associated with a worse prognosis and lower rates of event-free survival and overall survival. However, it was shown that there is no difference in prognosis between patients with AML-MRC with a history of MDS and the remaining cases of AML-MRC (Weinberg et al., 2009; Arber et al., 2003). Besides, AML-MRC with the absence of cytogenetic abnormalities seem to have a better prognosis (Weinberg et al., 2009). Additionally, AML-MRC with NPM1 mutations and with or without cytogenetic abnormalities show a better prognosis (Haferlach et al., 2009). This was also shown for CEBPA mutations (Vardiman and Reichard, 2015). Therefore AML-MRC with NPM1 or CEBPA mutations are excluded from the AML-MRC category in the WHO classification 2016 (Arber et al., 2016). The prognosis of AML-MRC particularly in context of multilineage dysplasia remains controversial (Vardiman and Reichard, 2015). In patients who have undergone allogeneic HSCT there is no prognostic difference in AML-MRC patients compared to AML not otherwise specified (AML-NOS) (Ikegawa et al., 2016).

## Cytogenetics

### Cytogenetics morphological

Following the WHO classification, cases of AML with MDS-related cytogenetic abnormalities meet the criteria of AML-MRC. MDS and AML-MRC may show complex karyotype and with predominantly unbalanced chromosomal abnormalities (Vardiman and Reichard, 2015; Miesner et al., 2010). A complex karyotype is defined as three or more unrelated chromosomal abnormalities and is differentiated into unbalanced and balanced chromosomal abnormalities (see Figure 1). A complex karyotype can lead to aberrant expression pattern of regulating genes and is often associated with a poor prognosis. Likewise, it is assumed that autosomal monosomy (2 or more autosomal monosomies or 1 autosomal monosomy plus one or more other chromosomal abnormalities) is associated with a poor prognosis.



**Figure 1.** Karyotype analysis with MDS related cytogenetic abnormalities: 46,XX,t(4;6)(q21;23),del(5)(q11.2q35),del(7)(q11.2q36),+8,add(11)(p15),del(12)(p12p13),-17. Commonly seen in MDS is the deletion of 5 and 7 (stars) and/or monosomy 17 (cross) (Miesner et al., 2010).

The most common monosomies in AML and MDS are monosomies 5 and 7 which are known for its poor prognosis (Takahashi, 2011; Cazzola et al., 2013). Table 1 shows the commonly occurring balanced and unbalanced chromosomal abnormalities.

<b>Complex Karyotype</b>	>3 unrelated abnormalities, none of which are included in the AML with recurrent genetic abnormalities subgroup
<b>Unbalanced abnormalities</b>	-7/del(7q) -5/del(5q) i(17q)/t(17p) -13/del(13q) del(11q) del(12p)/t(12p) idic(X)(q13)
<b>Balanced abnormalities</b>	t(11;16)(q23;p13.3) t(3;21)(q26.2;q22.1) t(2;11)(p21;q23) t(1;3)(p36.3;q21.1) t(5;12)(q33;p12) t(5;7)(q33;q11.2) t(5;17)(q33;p13) t(5;10)(q33;q21) t(3;5)(q25;q34)

**Table 1.** Cytogenetic abnormalities for AML with myelodysplasia-related features (modified from Vardiman and Reichard et al. 2015).

Common gene arrangements and their effects are displayed in Table 2. According to the 2016 WHO classification the MDS related cytogenetic abnormality del(9q) is no longer considered a AML-MRC defining abnormality. Since del(9q) commonly occurs together with NPM1 or bi-allelic CEBPA mutations it is also associated with a better

outcome. The same is true for trisomy 8, del(20q) and loss of chromosome Y (Pabst et al., 2009; Wu et al., 2013).

Gene arrangement	Effect
5q33	activation of the platelet-derived growth factor- $\beta$ (PDGFRB)
3q26 (MECOM (EVI1) locus)	Impaired EVI1 expression (poor prognosis)
3q21 (GATA2 locus)	Impaired EVI1 expression (poor prognosis)
11q23 (KMT2A (MLL) locus)	Clonal evolution and disease progression in acute leukemia
t(3;5)	fusion product NPM1 / MLF1

**Table 2.** Common gene arrangements in AML-MRC (Vardiman and Reichard, 2015; Arber et al., 2003; Heldin and Lennartsson, 2013; Zuo et al., 2016; Lim et al., 2010)

## Genes involved and proteins

As mentioned in Prognosis, the NPM1 mutation can present with multilineage dysplasia and is associated with a better outcome. However, there are no genetic somatic mutations fully specific for AML-MRC. As the subcategory AML-MRC represents almost 50% of all AML cases there can be found all common somatic mutations of AML concomitantly. In case of an AML-MRC with a history of MDS commonly mutated genes in MDS should also be considered, e.g. SF3B1 which is associated with the formation of ring sideroblasts in MDS (Malcovati et al., 2014). Somatic mutations have prognostic value and are assumed to play a critical role in leukemogenesis.

They can affect signal transduction, DNA methylation, chromatin modification, transcriptional regulation, RNA splicing and cohesion- complexes. The most commonly mutated genes in AML are FLT3, NPM1, CEBPA besides many more (Cancer and Atlas, 2013; Malcovati et al., 2014). Following the 2016 WHO classification an AML-MRC with presence of NPM1 and bi-allelic CEBPA mutation is not considered a AML-MRC anymore as these gene mutations are associated with a better outcome (Arber et al., 2003; Haferlach et al., 2009; Pabst et al., 2009) In contrast FLT3 mutations are associated with genetic abnormalities and a worse clinical outcome (Bibault et al., 2015).

## References

- Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*. 2016 May 19;127(20):2391-405
- Arber DA, Stein AS, Carter NH, Ikle D, Forman SJ, Slovak ML. Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. *Am J Clin Pathol*. 2003 May;119(5):672-80
- Ayar SP, Ravula S, Polski JM. Granulocyte, monocyte and blast immunophenotype abnormalities in acute myeloid leukemia with myelodysplasia-related changes. *Ann Clin Lab Sci*. 2014 Winter;44(1):3-9
- Bibault JE, Figeac M, Hélevaut N, Rodriguez C, Quief S, Sebda S, Renneville A, Nibourel O, Rousselot P, Gruson B, Dombret H, Castaigne S, Preudhomme C. Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia. *Oncotarget*. 2015 Sep 8;6(26):22812-21
- Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, Hoadley K, Triche TJ Jr, Laird PW, Baty JD, Fulton LL, Fulton R, Heath SE, Kalicki-Weizer J, Kandoth C, Klco JM, Koboldt DC, Kanchi KL, Kulkarni S, Lamprecht TL, Larson DE, Lin L, Lu C, McLellan MD, McMichael JF, Payton J, Schmidt H, Spencer DH, Tomasson MH, Wallis JW, Wartman LD, Watson MA, Welch J, Wendt MC, Ally A, Balasundaram M, Birol I, Butterfield Y, Chiu R, Chu A, Chuah E, Chun HJ, Corbett R, Dhalla N, Guin R, He A, Hirst C, Hirst M, Holt RA, Jones S, Karsan A, Lee D, Li HI, Marra MA, Mayo M, Moore RA, Mungall K, Parker J, Pleasance E, Plettner P, Schein J, Stoll D, Swanson L, Tam A, Thiessen N, Varhol R, Wye N, Zhao Y, Gabriel S, Getz G, Sougnez C, Zou L, Leiserson MD, Vandin F, Wu HT, Applebaum F, Baylin SB, Akbani R, Broom BM, Chen K, Motter TC, Nguyen K, Weinstein JN, Zhang N, Ferguson ML, Adams C, Black A, Bowen J, Gastier-Foster J, Grossman T, Lichtenberg T, Wise L, Davidsen T, Demchok JA, Shaw KR, Sheth M, Sofia HJ, Yang L, Downing JR, Eley G. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med*. 2013 May 30;368(22):2059-74
- Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. *Blood*. 2013 Dec 12;122(25):4021-34
- Davis KL, Marina N, Arber DA, Ma L, Cherry A, Dahl GV, Heerema-McKenney A. Pediatric acute myeloid leukemia as classified using 2008 WHO criteria: a single-center experience. *Am J Clin Pathol*. 2013 Jun;139(6):818-25
- Deschler B, Lübbert M. Acute myeloid leukemia: epidemiology and etiology. *Cancer*. 2006 Nov 1;107(9):2099-107
- Estey E, Döhner H. Acute myeloid leukaemia. *Lancet*. 2006 Nov 25;368(9550):1894-907
- Falini B, Maciejewski K, Weiss T, Bacher U, Schnittger S, Kern W, Kohlmann A, Klein HU, Vignetti M, Piciocchi A, Fazi P, Martelli MP, Vitale A, Pileri S, Miesner M, Santucci A, Haferlach C, Mandelli F, Haferlach T. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). *Blood*. 2010 May 6;115(18):3776-86
- Font P, Subirá D, Mtnéz-Chamorro C, Castañón S, Arranz E, Ramiro S, Gil-Fernández JJ, López-Pascual J, Alonso A, Pérez-Sáenz MA, Alaez C, Renedo M, Blas C, Escudero A, Fdez-Rañada JM. Evaluation of CD7 and terminal deoxynucleotidyl transferase (TdT) expression in CD34+ myeloblasts from patients with myelodysplastic syndrome. *Leuk Res*. 2006 Aug;30(8):957-63
- Haferlach C, Mecucci C, Schnittger S, Kohlmann A, Mancini M, Cuneo A, Testoni N, Rege-Cambrin G, Santucci A, Vignetti M, Fazi P, Martelli MP, Haferlach T, Falini B. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. *Blood*. 2009 Oct 1;114(14):3024-32
- Heldin CH, Lennartsson J. Structural and functional properties of platelet-derived growth factor and stem cell factor receptors. *Cold Spring Harb Perspect Biol*. 2013 Aug 1;5(8):a009100
- Ikegawa S, Doki N, Kurosawa S, Yamaguchi T, Sakaguchi M, Harada K, Yamamoto K, Hino Y, Shingai N, Senoo Y, Watanabe K, Igarashi A, Najima Y, Kobayashi T, Kakihana K, Sakamaki H, Ohashi K. Allogeneic hematopoietic stem cell transplant overcomes poor prognosis of acute myeloid leukemia with myelodysplasia-related changes. *Leuk Lymphoma*. 2016;57(1):76-80
- Kumar CC. Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. *Genes Cancer*. 2011 Feb;2(2):95-107
- Lim G, Choi JR, Kim MJ, Kim SY, Lee HJ, Suh JT, Yoon HJ, Lee J, Lee S, Lee WI, Park TS. Detection of t(3;5) and NPM1/MLF1 rearrangement in an elderly patient with acute myeloid leukemia: clinical and laboratory study with review of the literature. *Cancer Genet Cytogenet*. 2010 Jun;199(2):101-9
- Malcovati L, Papaemmanuil E, Ambaglio I, Elena C, Galli A, Della Porta MG, Travaglini E, Pietra D, Pascutto C, Ubezio M, Bono E, Da Vià MC, Brisci A, Bruno F, Cremonesi L, Ferrari M, Boveri E, Invernizzi R, Campbell PJ, Cazzola M. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. *Blood*. 2014 Aug 28;124(9):1513-21
- Miesner M, Haferlach C, Bacher U, Weiss T, Maciejewski K, Kohlmann A, Klein HU, Dugas M, Kern W, Schnittger S, Haferlach T. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC). *Blood*. 2010 Oct 14;116(15):2742-51
- Pabst T, Eyholzer M, Fos J, Mueller BU. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated

with favourable prognosis. *Br J Cancer*. 2009 Apr 21;100(8):1343-6

Takahashi S. Current findings for recurring mutations in acute myeloid leukemia. *J Hematol Oncol*. 2011 Sep 14;4:36

van Dongen JJ, Lhermitte L, Böttcher S, Almeida J, van der Velden VH, Flores-Montero J, Rawstron A, Asnafi V, Lécrovisse Q, Lucio P, Mejstrikova E, Szczepański T, Kalina T, de Tute R, Brüggemann M, Sedek L, Cullen M, Langerak AW, Mendonça A, Macintyre E, Martin-Ayuso M, Hrusak O, Vidriales MB, Orfao A. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. *Leukemia*. 2012 Sep;26(9):1908-75

Vardiman J, Reichard K. Acute Myeloid Leukemia With Myelodysplasia-Related Changes. *Am J Clin Pathol*. 2015 Jul;144(1):29-43

Weinberg OK, Hasserjian RP, Li B, Pozdnyakova O. Assessment of myeloid and monocytic dysplasia by flow cytometry in de novo AML helps define an AML with myelodysplasia-related changes category. *J Clin Pathol*. 2017 Feb;70(2):109-115

Weinberg OK, Seetharam M, Ren L, Seo K, Ma L, Merker

JD, Gotlib J, Zehnder JL, Arber DA. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. *Blood*. 2009 Feb 26;113(9):1906-8

Wu H, Bian S, Chu J, Zhong X, Sun H, Zhang B, Lu Z. Characteristics of the four subtypes of myelodysplastic/myeloproliferative neoplasms. *Exp Ther Med*. 2013 May;5(5):1332-1338

Xu XQ, Wang JM, Gao L, Qiu HY, Chen L, Jia L, Hu XX, Yang JM, Ni X, Chen J, Lü SQ, Zhang WP, Song XM. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients. *Am J Hematol*. 2014 Sep;89(9):874-81

Zuo W, Wang SA, DiNardo C, Yabe M, Li S, Medeiros LJ, Tang G. Acute leukaemia and myelodysplastic syndromes with chromosomal rearrangement involving 11q23 locus, but not MLL gene. *J Clin Pathol*. 2017 Mar;70(3):244-249

---

*This article should be referenced as such:*

Nagy A, Neubauer A. Acute myeloid leukemia with myelodysplasia related changes. *Atlas Genet Cytogenet Oncol Haematol*. 2017; 21(11):404-408.

---